Search
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin is a progestin used as the progestational component of combined hormonal contraceptives. It is administered transdermally in combination with the estrogen ethinyl estradiol, delivering both hormones systemically over a 7-d...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEnclomiphene
go.drugbank.com/drugs/DB06735InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesPinacidil
go.drugbank.com/drugs/DB06762ApprovedPinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance. The above processes result in reduced blood press...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSulconazole
go.drugbank.com/drugs/DB06820ApprovedSulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic derma...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsParecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalParecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is inj...
Synonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAzilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. … It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEllagic acid
go.drugbank.com/drugs/DB08846InvestigationalEllagic acid is present in several fruits such as cranberries, strawberries, raspberries, and pomegranates. In pomegranates, there are several therapeutic compounds but ellagic acid is the most active and abundant. Ellagic acid is also p...
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...
Categories: Receptor Protein-Tyrosine Kinases, antagonists & inhibitors, Cytochrome P-450 SubstratesVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalVemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxiko...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates